Nothing Special   »   [go: up one dir, main page]

DK1416917T3 - Vandig dispersion, der omfatter stabile nanopartikler af et vanduoplöseligt aktivt stof og en excipiens som middellangkædede triglycerider (MCT) - Google Patents

Vandig dispersion, der omfatter stabile nanopartikler af et vanduoplöseligt aktivt stof og en excipiens som middellangkædede triglycerider (MCT)

Info

Publication number
DK1416917T3
DK1416917T3 DK02745697T DK02745697T DK1416917T3 DK 1416917 T3 DK1416917 T3 DK 1416917T3 DK 02745697 T DK02745697 T DK 02745697T DK 02745697 T DK02745697 T DK 02745697T DK 1416917 T3 DK1416917 T3 DK 1416917T3
Authority
DK
Denmark
Prior art keywords
water
mct
excipient
active substance
aqueous dispersion
Prior art date
Application number
DK02745697T
Other languages
Danish (da)
English (en)
Inventor
Ulf Olsson
Tommy Urban Skantze
Per Lennart Lindfors
Corswant Lars Christian Von
Schantz Anna Elisa Zzackrisson
Pia Margaretha Cecilia Skantze
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0119081A external-priority patent/GB0119081D0/en
Priority claimed from GB0212463A external-priority patent/GB0212463D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1416917T3 publication Critical patent/DK1416917T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Dental Preparations (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK02745697T 2001-08-06 2002-08-01 Vandig dispersion, der omfatter stabile nanopartikler af et vanduoplöseligt aktivt stof og en excipiens som middellangkædede triglycerider (MCT) DK1416917T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0119081A GB0119081D0 (en) 2001-08-06 2001-08-06 Process
GB0212463A GB0212463D0 (en) 2002-05-30 2002-05-30 Process
PCT/GB2002/003583 WO2003013472A1 (en) 2001-08-06 2002-08-01 Aqueous dispersion comprising stable nanoparticles of a water-insoluble active and an excipient like middle chain triglycerides (mct)

Publications (1)

Publication Number Publication Date
DK1416917T3 true DK1416917T3 (da) 2007-09-17

Family

ID=26246405

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02745697T DK1416917T3 (da) 2001-08-06 2002-08-01 Vandig dispersion, der omfatter stabile nanopartikler af et vanduoplöseligt aktivt stof og en excipiens som middellangkædede triglycerider (MCT)

Country Status (20)

Country Link
US (1) US20050009908A1 (el)
EP (1) EP1416917B1 (el)
JP (1) JP4714412B2 (el)
KR (1) KR100914113B1 (el)
CN (1) CN1254233C (el)
AT (1) ATE365537T1 (el)
AU (1) AU2002317409B2 (el)
BR (1) BR0211705A (el)
CA (1) CA2456180C (el)
CY (1) CY1107059T1 (el)
DE (1) DE60220923T2 (el)
DK (1) DK1416917T3 (el)
ES (1) ES2287293T3 (el)
HK (1) HK1064048A1 (el)
IL (2) IL160103A0 (el)
MX (1) MXPA04001071A (el)
NO (1) NO20040484L (el)
NZ (1) NZ530916A (el)
PT (1) PT1416917E (el)
WO (1) WO2003013472A1 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2004111033A1 (en) * 2003-06-18 2004-12-23 Astrazeneca Ab 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
EP1915131A4 (en) * 2005-08-12 2012-07-25 Astrazeneca Ab PROCESS
WO2008013785A2 (en) * 2006-07-24 2008-01-31 Singh-Broemer And Company, Inc. Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening
US20100260691A1 (en) * 2006-07-31 2010-10-14 Narayanan Kolazi S Aqueous compositions containing a hydrophobic material
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20100068287A1 (en) * 2007-02-09 2010-03-18 Astrazeneca Ab Process for Preparation of a Stable Dispersion of Solid Amorphous Submicron Particles in an Aqueous Medium
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
WO2009011861A1 (en) * 2007-07-16 2009-01-22 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
EP2244714A4 (en) * 2008-02-08 2012-06-06 Poniard Pharmaceuticals Inc USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
BRPI1004808B1 (pt) * 2010-10-27 2020-09-29 Embrapa - Empresa Brasileira De Pesquisa Agropecuária Composições baseadas em nanopartículas de própolis, processos de obtenção e uso
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
KR102045732B1 (ko) * 2012-12-28 2019-11-18 엘지디스플레이 주식회사 온도감응형 계면활성제를 이용한 수용성 나노입자의 제조방법
PT106738B (pt) * 2013-01-09 2015-06-08 Hovione Farmaciencia Sa Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico
CN105121559A (zh) * 2013-02-08 2015-12-02 巴斯夫欧洲公司 通过反应喷雾干燥的无机/有机复合材料的制备
US20190110993A1 (en) * 2017-09-12 2019-04-18 Raj Selvaraj Solid Nanoparticle Formulation of Water Insoluble Pharmaceutical Substances with Reduced Ostwald Ripening
EP4426694A1 (en) 2021-11-05 2024-09-11 Cinclus Pharma Holding AB (publ) Polymorphs of the hydrochloride salt of linaprazan glurate

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2224131B2 (de) * 1972-05-17 1974-06-27 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur Gewinnung des Enzyms Cholesterinoxydase, welches Cholesterin mit O tief 2 zu Cholestenon und H tief 2 O tief 2 oxydiert
US4348385A (en) * 1980-11-17 1982-09-07 Mobay Chemical Corporation Flowable pesticides
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
US4799962A (en) * 1987-12-24 1989-01-24 Aqualon Company Water-soluble polymer dispersion
US5145648A (en) * 1988-06-28 1992-09-08 Matsushita Electric Industrial Co., Ltd. Exhaust smoke purifier apparatus
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
CA2044706C (en) * 1990-06-15 2003-02-25 Michael Midler Jr. Crystallization method to improve crystal structure and size
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1993010768A1 (de) * 1991-12-05 1993-06-10 Alfatec-Pharma Gmbh Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5468604A (en) * 1992-11-18 1995-11-21 Eastman Kodak Company Photographic dispersion
GB9319129D0 (en) * 1993-09-15 1993-11-03 Dowelanco Ltd Storage and dilution of stable aqueous dispersions
SE9303281D0 (sv) * 1993-10-07 1993-10-07 Astra Ab New formulation
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
ATE257698T1 (de) * 1996-10-03 2004-01-15 Hermes Biosciences Inc Hydrophile mikropartikel und verfahren zu deren herstellung
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations

Also Published As

Publication number Publication date
EP1416917B1 (en) 2007-06-27
CN1254233C (zh) 2006-05-03
JP4714412B2 (ja) 2011-06-29
AU2002317409B2 (en) 2007-06-21
ATE365537T1 (de) 2007-07-15
DE60220923D1 (de) 2007-08-09
CA2456180A1 (en) 2003-02-20
KR20040025739A (ko) 2004-03-25
NO20040484L (no) 2004-03-31
BR0211705A (pt) 2004-09-28
EP1416917A1 (en) 2004-05-12
DE60220923T2 (de) 2008-03-06
WO2003013472A1 (en) 2003-02-20
PT1416917E (pt) 2007-08-16
HK1064048A1 (en) 2005-01-21
KR100914113B1 (ko) 2009-08-27
IL160103A0 (en) 2004-06-20
CN1564677A (zh) 2005-01-12
MXPA04001071A (es) 2004-05-20
CY1107059T1 (el) 2012-10-24
US20050009908A1 (en) 2005-01-13
JP2005500362A (ja) 2005-01-06
IL160103A (en) 2008-11-26
ES2287293T3 (es) 2007-12-16
NZ530916A (en) 2005-07-29
CA2456180C (en) 2011-10-11

Similar Documents

Publication Publication Date Title
DK1416917T3 (da) Vandig dispersion, der omfatter stabile nanopartikler af et vanduoplöseligt aktivt stof og en excipiens som middellangkædede triglycerider (MCT)
EP1829530A3 (en) Stabilization of active agents by formulation into nanoparticulate form
BR0210948A (pt) Micropartìculas de lignina para liberação controlada de ativos agrìcolas
WO2005060431A3 (en) System and method for manipulating and processing materials using holographic optical trapping
EP2241308A3 (en) Method for coating fine particle with lipid membrane
WO2006113808A3 (en) Methods of making and modifying porous devices for biomedical applications
WO2000066679A3 (en) Electrochromic media with concentration-enhanced stability, process for the preparation thereof and use in electrochromic devices
NZ593214A (en) Compounds and Processes for preparing serine protease inhibitors
DE60234420D1 (de) Haarbehandlungsmittel
WO2002060578A1 (fr) Dispositif servant a activer une substance au moyen d'une structure active et dispositif servant a generer un gaz
AU2003230658A1 (en) Microparticles and method for their production
WO2007142618A3 (en) High concentrated, biocidally active compositions and aqueous mixtures and methods of making the same
WO2004084860A3 (en) Methods for the comminution and stabilization of small particles in suspension
ATE399566T1 (de) Stabile dispersion fester teilchen mit einer wasserunlöslichen pyrazin-verbindung
WO2005038948A3 (en) Nanosized silver oxide powder
ATE449643T1 (de) Verfahren zur stabilisierung von peroxycarbonsäuren in tensidhaltigen dispersionen
WO2001062088A3 (en) Safening high concentrations of phytocatalysts
NO20060109L (no) Fremgangsmate for fremstilling av alfa- 1antitrypsinlosning
NO20030768L (no) Fremgangsmåte for stabilisering av småpartikkelmateriale
ATE440594T1 (de) Herstellung von kolloidale teilchen enthaltenden pulvern
ITSA20030013A1 (it) Manufatti microporosi e nanoporosi a base di
DK1775285T3 (da) Fremgangsmåde til krystallisation af bicalutamid
WO2005037446A3 (en) Applying imprinting material to substrates employing electromagnetic fields
FI20010164A0 (fi) Menetelmä parantuneen stabiliteetin omaavien natriumperkarbonaattirakeiden valmistamiseksi
JP2010126492A (ja) 還元型CoQ10−CD包接体の製造方法